# Whole-body MRI plus blood DNA surveillance for people with Li-Fraumeni syndrome

Source: https://onco.cc/ideas/idea-prev-li-fraumeni-mri-plus-cfdna/  
OnCo record `idea-prev-li-fraumeni-mri-plus-cfdna` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

People with an inherited TP53 mutation face a near-certain lifetime cancer risk. Yearly whole-body MRI catches cancers early; adding blood DNA tests may catch them earlier still.

## Summary

People with an inherited TP53 mutation face a near-certain lifetime cancer risk, so this idea builds a global Li-Fraumeni registry with standardised whole-body MRI surveillance plus prospective cell-free DNA and fragmentomics testing, to learn whether blood adds lead time over imaging. The Toronto Protocol of whole-body MRI, brain MRI and ultrasound already improved outcomes, the very high prior probability makes positive predictive value acceptable, and the multiplicity of tumour types favours a tumour-agnostic blood test. The test follows a 1,000-carrier prospective cohort for five years. At early-clinical maturity it addresses the bottlenecks Inherited risk is mostly unidentified and The hardest cancers are found late.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Adding cell-free DNA surveillance to imaging detects at least 30% of incident cancers before imaging, with lead time of six months or more.
- Rationale: Very high prior probability makes positive predictive value acceptable, and the multiplicity of tumour types favours a tumour-agnostic blood test.
- Proposed test: Follow a 1,000-carrier prospective cohort over five years.
- Maturity: early-clinical
- Actor: research

## Sources

- Bottleneck evidence (Inherited risk is mostly unidentified): Childers et al., National estimates of genetic testing in women with breast or ovarian cancer (JCO 2017): https://doi.org/10.1200/JCO.2017.73.6314

## Connected records

- cancers: [Sarcomas (soft tissue, bone, GIST)](https://onco.cc/cancers/sarcoma/)
- fronts: [Imaging](https://onco.cc/fronts/imaging/), [Prevention & Risk](https://onco.cc/fronts/prevention/)
- technologies: [Liquid biopsy (ctDNA)](https://onco.cc/technologies/liquid-biopsy/), [Whole-body MRI](https://onco.cc/technologies/whole-body-mri/)
- targets: [TP53](https://onco.cc/targets/tp53/)
- bottlenecks: [Inherited risk is mostly unidentified](https://onco.cc/bottlenecks/b-hereditary-risk/), [The hardest cancers are found late](https://onco.cc/bottlenecks/b-early-detection/)
- key papers: [National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer](https://onco.cc/key-papers/paper-childers-j-clin-oncol/), [Vogelstein, Lane and Levine 2000: surfing the p53 network](https://onco.cc/key-papers/paper-vogelstein-surfing-p53-network-nature-2000/)

---
JSON: https://onco.cc/api/v1/entities/idea-prev-li-fraumeni-mri-plus-cfdna.json